[5] [6] Whilst Ozempic has demonstrated significant efficacy in glycaemic control and modest weight reduction, patients and healthcare professionals often enquire about its potential effects on micronutrient status, including iron levels
While PAP may be beneficial in a subset of patients with OSA, emerging preclinical and clinical data suggest it may potentially cause harm in others [27], particularly at higher pressures [28], though this requires rigorous validation in future studies
Newer dual and triple agonists like retatrutide are also entering the research landscape
Always consult your healthcare provider to determine the most appropriate treatment plan for your specific smoking cessation needs
When B12 levels drop, fatigue is one of the earliest symptoms
Research continues to strengthen the connection between Semaglutide and chronic kidney disease